Loading
BICYCLE THERAPEUTICS plc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by BAKER BROS. ADVISORS LP, was filed 17 Dec 2024.
Insider Decl.
439
Thresholds
n/a
Buy Volume
€52M
18 ops. · all time
Sell Volume
€26M
249 ops. · all time
Who traded when
BuySaleTravis Alvin Thompson23 sales
Kevin Lee16 sales
Michael Charles Ferguson Hannay16 sales
Michael Skynner16 sales
Baker Bros. Advisors LP10 buys
Jennifer Scott Perry10 sales
+5 other insiders
Since the insiders bought
- -55.8%Entry US$15.31 · Close at T+365 US$6.77
- +47.8%Entry US$11.70 · Close at T+365 US$17.29
- +53.4%Entry US$11.20 · Close at T+365 US$17.18
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate BICYCLE THERAPEUTICS plc Buy (bullish), based on 6 analysts. Average price target: US$9.50.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$3.60
Analyst consensus
6 analystsBuy
US$5.00Target US$9.50(+164%)US$14.00
Income statement
RevenueUS$72.6M
EBITDA-US$212.2M-292% margin
Net income-US$219M-301.7% margin
Valuation
PER (forward)-1.6x
P/Book0.5x
Beta1.68
Balance sheet & cash
Market capUS$251.3M
Total debtUS$16.9M
Free Cash Flow-US$252M
Debt / Equity3%
Profitability & ownership
ROE-32.3%
ROA-17.9%
% insiders4.4%
% institutions71.9%
Last declaration on 7 October 2026
Declarations439 total
30 shares@ US$3.570.0000% mcap0.6% of flowOrdinary SharesSEC:0002119908-26-000013:0
3,431 shares@ US$3.470.0042% mcap93.4% of flowOrdinary SharesSEC:0002079922-26-000006:0
1,942 shares@ US$3.470.0024% mcap4.6% of flowOrdinary SharesSEC:0001776582-26-000010:0
503 shares@ US$3.570.0006% mcap1.2% of flowOrdinary SharesSEC:0001776582-26-000010:1
1,572 shares@ US$3.470.0019% mcap11.0% of flowOrdinary SharesSEC:0002015378-26-000010:0
242 shares@ US$3.570.0003% mcap1.7% of flowOrdinary SharesSEC:0002015378-26-000010:1
80 shares@ US$3.560.0001% mcap1.6% of flowOrdinary SharesSEC:0002119908-26-000011:1
326 shares@ US$3.780.0004% mcap6.8% of flowOrdinary SharesSEC:0002119908-26-000011:2
6,167 shares@ US$3.470.0076% mcap1.2% of flowOrdinary SharesSEC:0001776938-26-000008:0
1,638 shares@ US$3.570.0021% mcap0.3% of flowOrdinary SharesSEC:0001776938-26-000008:1
893 shares@ US$3.470.0011% mcap9.7% of flowOrdinary SharesSEC:0001983944-26-000014:0
79 shares@ US$3.570.0001% mcap0.9% of flowOrdinary SharesSEC:0001983944-26-000014:1
1,094 shares@ US$3.470.0014% mcap21.0% of flowOrdinary SharesSEC:0002119908-26-000011:0
9,000 shares@ US$3.47010.013% mcap1.8% of flowCommon StockSEC144:0001972481-26-000290
819 shares@ US$4.270.0014% mcap12.0% of flowOrdinary SharesSEC:0001983944-26-000008:0
104 shares@ US$4.310.0002% mcap1.5% of flowOrdinary SharesSEC:0001983944-26-000008:1
1,506 shares@ US$4.270.0025% mcap14.6% of flowOrdinary SharesSEC:0002015378-26-000006:0
255 shares@ US$4.310.0004% mcap2.5% of flowOrdinary SharesSEC:0002015378-26-000006:1
1,036 shares@ US$4.270.0017% mcap34.2% of flowOrdinary SharesSEC:0002119908-26-000007:0
43 shares@ US$4.310.0001% mcap1.4% of flowOrdinary SharesSEC:0002119908-26-000007:1
333 shares@ US$4.340.0006% mcap11.2% of flowOrdinary SharesSEC:0002119908-26-000007:2
1,859 shares@ US$4.270.0031% mcap5.7% of flowOrdinary SharesSEC:0001776582-26-000006:0
532 shares@ US$4.310.0009% mcap1.6% of flowOrdinary SharesSEC:0001776582-26-000006:1
5,905 shares@ US$4.270.0098% mcap1.4% of flowOrdinary SharesSEC:0001776938-26-000006:0
1,737 shares@ US$4.310.0029% mcap0.4% of flowOrdinary SharesSEC:0001776938-26-000006:1
25 of 439 declarations
About BICYCLE THERAPEUTICS plc
At BICYCLE THERAPEUTICS plc, a health care company listed on Nasdaq, sales are frequent but smaller than purchases: 249 sales worth EUR 26,020,716 (median EUR 17,355) against 21 purchases worth EUR 61,296,039 (median EUR 3,204,834), or 8% purchases among open-market trades. The record also holds 87 grants and 52 option exercises, across 439 filings from 35 filers.
The largest purchases come from Baker Bros. Advisors LP, filed as a director: EUR 7,470,172 on December 13, 2024 and EUR 6,680,160 on December 16, 2024. Carolyn Ng bought EUR 7,146,805 on May 27, 2019, and between May 27, 2019 and May 29, 2019 nine insiders bought EUR 41,051,626 in all. On the selling side, Pierre Legault sold EUR 5,029,299 on December 22, 2021 and EUR 2,255,379 the day before, and Nigel Crockett EUR 1,915,088 on July 13, 2021.
Read moreShow less
Kevin Lee, Chief Executive Officer, is the top filer, with 97 filings, 73 of them sales and none a purchase. The year 2021 has 129. The last twelve months line up 66 filings, 48 of them sales and none a purchase. The 21 purchases tracked to 90 days show a stored median of minus 37.5%, with none positive: past results, not a forecast. Market capitalisation is USD 251.3 million.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
